Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07668401 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Name: AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight — clinical trial record (NCT07668401)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AMAZE 13

StatusNot Yet Recruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2027-01-07

View on ClinicalTrials.gov ↗

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Amendment history 2 changes detected by DataLookout

2026-08-25

Trial sites expanded: 41 → 44 locations

2026-07-22

Trial sites expanded: 11 → 41 locations

Trial Details

NCT Number	NCT07668401
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Overweight
Enrollment	400 participants
Start Date	2027-01-07
Primary Completion	2029-01-11 (estimated)
Study Completion	2029-01-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-24